AstraZeneca Says Trial Results For Breast Cancer Drug Were Highly Positive
22 September 2023 - 4:53PM
Dow Jones News
By Christian Moess Laursen
AstraZeneca said trial results for its breast cancer drug
Dato-DXd showed significant improvement for the primary end-point
of so-called progression-free survival in patients.
The Anglo-Swedish pharma giant said Friday the drug--fully-named
datopotamab deruxtecan--showed a statistical significant and
clinically meaningful improvement compared with chemotherapy in
patients with breast cancer.
The safety profile of the treatment was consistent with previous
clinical trials in breast cancer with no new safety signals
identified, it said.
Progression-free survival means the length of time during and
after treatment of a disease, such as cancer, a patient lives with
the disease without it getting worse.
Dato-DXd is being jointly-developed with Japan's Daiichi
Sankyo.
Write to Christian Moess Laursen at christian.moess@wsj.com
(END) Dow Jones Newswires
September 22, 2023 02:38 ET (06:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Daiichi Sankyo (PK) (USOTC:DSNKY)
Historical Stock Chart
From Dec 2024 to Jan 2025
Daiichi Sankyo (PK) (USOTC:DSNKY)
Historical Stock Chart
From Jan 2024 to Jan 2025
